What was filed
Jagsonpal Pharmaceuticals told the NSE and BSE that, following internal restructuring, two existing executives have been designated as Senior Management Personnel effective 29 July 2026. The disclosure was made under Regulation 30 of the SEBI Listing Regulations.
The two are Mr. Balmukund Keshav, Deputy General Manager (Information Technology), and Mr. Sanjay Singhal, General Manager (CQA & Regulatory Affairs). Both are already with the company — this is a change in designation, not a fresh external hire.
Who they are
The filing describes Mr. Keshav as an IT leader who, over his 17-year tenure with Jagsonpal, has led digital transformation, ERP implementation, ITGC audits and enterprise infrastructure management.
Mr. Singhal, a pharmacy professional, has been with the company since 11 March 2020 and is described as a government-approved technical person for all dosage forms across its manufacturing and analytical divisions.
Why it matters to a holder
This is a governance-and-disclosure item rather than an operational or financial event. Designating executives as Senior Management Personnel brings them within the ambit of SEBI's Regulation 30 disclosure and related governance requirements. The filing states no change to the board, no financial impact and no departures; the term of appointment is marked "Not Applicable" for both.